INTRODUCTION
The natural peptide-like antibiotic negamycin (NEG) [2-(3,6-diamino-5-hydroxyhexanoyl)-methylhydrazino]acetic acid] (Figure 1A) , which exhibits inhibitory activity against Gram-negative and Gram-positive bacterial pathogens, was originally isolated from Streptomyces strains (Hamada et al., 1970) more than four decades ago. Although early biochemical experiments suggested that NEG inhibits protein synthesis (Mizuno et al., 1970a (Mizuno et al., , 1970b , its mode of action remained enigmatic because various in vitro studies suggested that it could inhibit steps of translation as diverse as initiation (Mizuno et al., 1970b) , decoding (Mizuno et al., 1970b; Uehara et al., 1972) , and termination (Uehara et al., 1974 (Uehara et al., , 1976b . The putative miscoding activity of NEG has made it an appealing candidate for the treatment of human genetic disorders caused by nonsense mutations. NEG or its synthetic analogs have demonstrated promising activity in stimulating premature stop codon bypass and partially restoring expression of several disease-related genes inactivated by nonsense mutations (Allamand et al., 2008; Arakawa et al., 2003; Floquet et al., 2011; Taguchi et al., 2012) . These findings have made the need to uncover the site and the mode of action of NEG even more compelling.
Lack of understanding of the mechanism of NEG action has been further exacerbated by conflicting reports regarding its binding site. In vitro studies suggested that NEG associates with an RNA fragment mimicking helix 44 of the small ribosomal subunit rRNA (Arakawa et al., 2003) , which harbors the binding site of miscoding-inducing aminoglycoside antibiotics (Griffey et al., 1999; Purohit and Stern, 1994) . However, ribosomes isolated from aminoglycoside resistant bacterial strains remained sensitive to NEG (Uehara et al., 1972) . Soaking crystals of the large ribosomal subunit of the archaeon Haloarcula marismortui with 5 mM NEG revealed that the antibiotic binds at an unexpected site that lies close to the opening of the nascent peptide exit tunnel (Schroeder et al., 2007) . Unfortunately, it was impossible to confirm the functional significance of the exit tunnel binding site because of the inability to isolate and map NEG-resistance mutations and due to the difficulty of crystallizing more physiologically relevant ribosome-antibiotic complexes (Corchuelo et al., 1981; Schroeder et al., 2007; Uehara et al., 1972) .
We reasoned that structural and functional studies of the antibiotic complexed to the ribosome in a functionally meaningful state could provide a more compelling and consistent view of the site and mode of NEG action. In this work, we solved the 2.7 Å resolution crystal structure of the bacterial (Thermus thermophilus) 70S ribosome in complex with mRNA, three tRNAs, and NEG, which shows binding of the drug to nine independent sites. Resistance mutations in 16S rRNA unequivocally identify one of them as the main site of antibiotic action. Here, NEG interacts simultaneously with 16S rRNA and the A-site bound tRNA. Strikingly, although the NEG binding site largely overlaps with that of tetracycline (TET), the two antibiotics exhibit opposite activities: while TET prevents accommodation of aminoacyl-tRNA in the A site due to a steric clash with the anticodon, NEG likely stabilizes tRNA binding, leading to an increase in the frequency of translation errors and inhibition of translocation.
RESULTS AND DISCUSSION
The Crystal Structure of NEG Bound to the Thermus thermophilus 70S Ribosome To identify the site of action of NEG in the bacterial ribosome, we solved the crystal structure of the T. thermophilus 70S ribosome in complex with NEG, a short mRNA, and three deacylated tRNAs at 2.7 Å resolution. The complex of 70S ribosomes with mRNA and tRNAs was first crystallized, and then crystals were soaked in 250 mM solution of NEG. It should be noted that this concentration of NEG significantly exceeded its IC 50 in the cellfree translation system ( Figure S1 available online); because the inhibitor's IC 50 and dissociation constant are only loosely correlated, we used a high NEG concentration in the crystallization experiments to ensure that the drug binding site was sufficiently saturated. The structure was solved by molecular replacement using the atomic coordinates of the T. thermophilus 70S ribosome (PDB entries 4QCM and 4QCN) (Polikanov et al., 2014b) . In order to localize the NEG binding site(s) within the ribosome, we calculated an unbiased difference Fourier map using the observed amplitudes from the crystal and the amplitudes and phases that were derived from a model of the ribosome without the bound antibiotic. Peaks of positive electron density resembling distinct features of the NEG chemical structure ( Figure 1A ) were observed at nine different locations in both copies of the ribosome in the asymmetric unit ( Figures 1B, 1C , and S2; Movie S1). Four of the NEG binding sites are located on the 30S subunit (Sites 1-4), while the remaining five sites are on the 50S subunit ). An atomic model of NEG was manually fitted into the difference Fourier map at each location, and their coordinates were refined. The statistics for data processing and refinement are shown in Table 1 .
The multitude of binding sites likely reflects promiscuous interactions of the small, flexible, positively charged antibiotic molecule with the large, porous ribosome built on a polyanionic RNA scaffold (Voss et al., 2006) . It is unlikely, therefore, that all of the observed binding sites are functionally relevant, moreover that the NEG concentration used for crystal soaking likely significantly exceeds physiologically relevant concentrations of the antibiotic. With one exception (Site 1), most of these pockets are located far from the known ribosomal functional centers. Furthermore, none of them overlap with the NEG binding site previously observed in the archaeal 50S subunit (Schroeder et al., 2007) or with the 16S rRNA helix 44, which was putatively implicated as the NEG-interacting partner by RNA fragment binding studies (Arakawa et al., 2003) . Some other antibiotics bind to several ribosomal sites, of which usually only one or few represent the true targets of drug action (Borovinskaya et al., 2007a; Brodersen et al., 2000; Pioletti et al., 2001; Schlü nzen et al., 2003) . Therefore, we used genetic tools to establish the site where NEG binding interferes with ribosome function.
Mapping the Site of NEG Action in the Bacterial Ribosome To determine the true site of action of NEG in the bacterial ribosome, we selected resistant mutants using the E. coli strain SQ110DTC that, besides being hypersensitive to a large range of antibiotics, possesses only one rrn allele that facilitates isolation of ribosomal mutations (Orelle et al., 2013) . Plating 10 9 cells onto an agar plate containing 160 mg/ml of NEG (5-fold the minimal inhibitory concentration [MIC] ) resulted in the appearance of several resistant colonies. Sequencing of the 23S rRNA gene did not reveal alterations at any position. However, in all sequenced NEG-resistant clones, mutations were found in the 16S rRNA gene. These mutations (U1052G, U1060A, and A1197U) were clustered in the middle section of helix 34 (h34) ( Figure 1D ). They are located in close proximity to the decoding center in the 30S ribosomal subunit, and most importantly, they are positioned immediately adjacent to the NEG Site 1 observed in our crystal structure ( Figure 1C ). In order to verify that h34 mutations found in the analyzed clones were necessary and sufficient to confer NEG resistance, two of the mutations, U1060A and A1197U, were individually engineered in the 16S rRNA gene of the rRNA operon in plasmid pAM552. Plasmids carrying the mutations were introduced into the antibiotic-hypersensitive DtolC variant of the E. coli strain SQ171 that lacks all the chromosomal rrn alleles (Asai et al., 1999; Bollenbach et al., 2009 ). The mutations increased NEG resistance 4-fold (U1060A) or 16-fold (A1197U) ( Table 2) . Therefore, in spite of the multiplicity of antibiotic binding sites observed in the crystal complex, the resistance mutations clustered around the drug-binding Site 1 in h34 of the 16S rRNA unequivocally identified it as the primary target of NEG action. Accordingly, we focus our subsequent analysis specifically on this site.
NEG Binding to the Site of Its Action Requires Proper
Configuration of the 16S rRNA Backbone In Site 1, the extended hydrophilic antibiotic forms multiple hydrogen bonds with the backbone of nucleotides 965, 966, Average B factor (overall), Å 2 59.5 R merge = P jI À hIij= P I, where I is the observed intensity and hIi is the average intensity from multiple measurements. R work = P jF obs À F calc j= P F obs . For calculation of R free , 5% of the truncated data set was excluded from the refinement. 
1054, and 1197 (Figures 2 and S3C
). The terminal carboxylic moiety of NEG forms a magnesium-mediated contact with the phosphate group of nucleotide 1052. None of the contacts of the antibiotic with the ribosome directly involve rRNA bases. Rather, the drug recognizes specific sugar-phosphate backbone atoms, whose proper spatial arrangement defines the position of the drug in its binding site. Therefore, the 16S rRNA resistance mutations that were identified, all of which disrupt h34 base pairs ( Figure 1D ), likely interfere with drug binding by changing the geometry of the h34 backbone. Two of the E. coli mutations, U1060A and A1197U, break the same base pair in h34 (Figure 1D) . It is noteworthy that in the T. thermophilus ribosome, which readily binds NEG, the U-A base pair at this location is replaced with the C-G base pair, underscoring the importance of Watson-Crick interactions rather than the identity of the nucleotide for the antibiotic binding. Disruption of the 1060-1197 base pair by NEG r mutations likely perturbs hydrogen bonding of the antibiotic to the residue 1197 backbone ( Figure 2E ). If this view is correct, then combining these two resistance mutations in the same cell would reconstitute the base-pair and hence restore sensitivity to the drug. Indeed, the simultaneous presence of U1060A and A1197U mutations in the E. coli 16S rRNA reverted NEG sensitivity to the wild-type level (Table 2) , thereby confirming that the proper structure of the h34 backbone is required for the efficient binding of the antibiotic to its site of action in the small ribosomal subunit.
NEG Interacts with the A-site tRNA
In fast-growing cells, the majority of the ribosomes are involved in active translation. Therefore, when cells are exposed to an antibiotic, the inhibitor interacts predominantly with the translating ribosomes associated with functional ligands such as mRNA, tRNAs, and translation factors. The contacts of the inhibitor with the ligands of translation can be pivotal for its inhibitory action. Thus, crystallographic structures of an antibiotic complexed to the ribosome in the functional state should more accurately reveal the mechanisms of drug action than structures of the inhibitor bound to the vacant ribosome or individual ribosomal subunits. Indeed, analysis of intermolecular contacts established by NEG in the Site 1 shows that the antibiotic forms extensive interactions with the anticodon of the A-site tRNA. The N4 secondary amine ( Figure 1A ) of NEG is at hydrogenbonding distance from the nonbridging oxygen atoms of the 5 0 phosphate of nucleotide 34 of the A-site tRNA ( Figure 2D ). In addition, the terminal carboxyl group of NEG interacts with the nonbridging oxygen of the 3 0 phosphate of the same tRNA residue via a hydrated magnesium ion, further strengthening the interactions of the drug with the tRNA. (A-C) Overview of the NEG binding Site 1 (yellow) in the T. thermophilus 70S ribosome viewed from three different perspectives. The 30S subunit is shown in light yellow; 50S subunit is light blue; mRNA is shown in magenta; and tRNAs are displayed in green (A site), dark blue (P site), and orange (E site). In (A), the 30S subunit is viewed from the intersubunit interface (50S subunit and A-site tRNA were removed for clarity). In (A) and (B), the location of helix 34 of 16S rRNA is highlighted by black outline. (D-F) Close-up views of the NEG binding Site 1 shown in panels (A), (B), and (C), respectively. Magnesium ion is shown in green. Nucleotides, whose mutations in E. coli confer NEG resistance, are boxed. See also Figure S3 and Movie S1.
Interaction of NEG with tRNA May Inhibit Translocation
The simultaneous multiple contacts of NEG with 16S rRNA and tRNA suggest that the drug may increase the affinity of tRNA to the A site, leading to some predictable consequences. Specifically, the tighter tRNA binding is expected to interfere with translocation because clearance of the A site and relocation of the tRNA-mRNA complex will require higher activation energy. We tested this possibility by analyzing the effect of NEG on translocation using a toe-printing assay (Hartz et al., 1988) . This approach allows for detection of the ribosome pausing on mRNA during in vitro translation; the pattern of transiently stalled ribosomes is indicative of the mode of antibiotic action (Orelle et al., 2013) . The well-known inhibitors of translocation, viomycin (VIO) or kanamycin (KAN) (Wilson, 2009) , cause the appearance of a series of evenly spaced weak toe-printing bands corresponding to ribosomes that have randomly paused during their progression through the mRNA codons (Orelle et al., 2013) (Figure 3A) . The presence of NEG in the translation reaction produces a set of bands whose positions coincide with those observed for VIO or KAN ( Figure 3A) , indicating similarity in the modes of action of these antibiotics. We noted that TET, which inhibits translation by preventing binding of aminoacyl-tRNA in the A site (Wilson, 2009) , also generates codon-spaced toeprinting bands (Orelle et al., 2013) (Figure 3A ). However, a number of the TET bands were shifted by one nucleotide relative to those of NEG, VIO, or KAN-a previously described toe-printing effect associated with the lack of an A-site tRNA in the stalled ribosome (Jerinic and Joseph, 2000; Orelle et al., 2013) . Thus, the results of toe-printing analysis argue that NEG exerts its action after accommodation of aminoacyl-tRNA in the A site and inhibits ribosome progression through mRNA, possibly by impeding translocation.
Of note, increasing concentration of NEG in the reaction did not increase the ribosome stalling at the earlier mRNA codons ( Figure S1B ). This result indicates that even at saturation NEG does not block translocation dramatically but only slows it down at each codon. Multiplication of even a weak inhibitory effect over many codons of a protein-coding gene would result in severe inhibition of protein production at a relatively low NEG concentration.
We further directly tested the effect of NEG on translocation in a model assay that monitors the EF-G-catalyzed relocation of the ribosome from the start AUG codon of the phage T4 gene 32 mRNA to the second UUU codon ( Figure 3B ). The presence of NEG decreased the extent of translocation at a 30 s time point corresponding to the kinetic slope of the reaction, thus confirming that binding of the antibiotic slows down progression of the ribosome along mRNA, likely due to impeded translocation. NEG May Induce Miscoding by Stabilizing AminoacyltRNA Binding in the A Site Antibiotics like paromomycin (PAR) or streptomycin (STR), which similarly to NEG may strengthen tRNA binding to the A site, promote miscoding (Karimi and Ehrenberg, 1994; Peske et al., 2004) ( Figure S4 ). Previous data indicated that NEG might induce amino acid misincorporation in bacterial cell-free extracts (Mizuno et al., 1970b; Uehara et al., 1972) . In order to verify whether NEG stimulates in vivo miscoding in bacteria, we engineered a reporter system in which a premature UGA stop codon interrupts the bla gene in the pBR322 plasmid (''pBR322bla-stop''), preventing expression of functional b-lactamase. Survival of pBR322bla-stop-transformed cells in the presence of the b-lactam antibiotic ampicillin depends solely upon the ability of the translating ribosomes to bypass the premature stop codon in the bla gene by misreading it as a sense codon. In the absence of other antibiotics, growth of the lawn of cells transformed with pBR322bla-stop on a LB-agar plate is inhibited by 25 mg/ ml ampicillin ( Figure 3C ). In contrast, diffusion of NEG from a disk impregnated with the drug allowed cell growth on the ampicillin plate ( Figure 3C) . Similarly, PAR, a translation errorinducing aminoglycoside, also promoted growth on ampicillin, while spectinomycin (SPC), which does not induce miscoding (Wilson, 2009) , did not. Expression of the catalytically active b-lactamase in the cells surrounding the disks with NEG or PAR was confirmed by staining with nitrocefin, an indicator of b-lactamase activity (O'Callaghan et al., 1972) . This result demonstrates substantial miscoding activity of NEG in bacterial cells, which likely stems from its ability to promote illegitimate aminoacyl-tRNA binding to the ribosomal A site programmed with stop codon. While ''traditional'' miscoding antibiotics (e.g., PAR or STR) stimulate tRNA binding by altering the conformation of the A site (Ogle and Ramakrishnan, 2005) , NEG apparently achieves a similar effect by establishing direct interactions with the A-site tRNA. We should indicate, however, that our data are insufficient to comment on codon or tRNA specificity of NEGinduced miscoding.
The readthrough activity we observed in bacteria is reminiscent of the reported NEG ability to stimulate premature stop codon bypass in mammalian cells (Allamand et al., 2008; Arakawa et al., 2003) . The alignment of the structures of the 70S ribosome in complex with NEG and the vacant yeast 80S ribosome (Ben-Shem et al., 2011) showed that the drug could form similar interactions with both bacterial 16S rRNA and eukaryotic 18S rRNA, despite their evolutionary divergence (Figure 4 ). Therefore, it is possible that, in both the bacterial and eukaryotic ribosomes, NEG induces stop codon readthrough by binding to the same site in the vicinity of h34 of rRNA of the small subunit.
Our structure of the ribosome-NEG functional complex offers a possible explanation for the previously reported varying miscoding capacity of NEG derivatives (Uehara et al., 1976a) . The placement of the drug in Site 1 is fixed by the interaction between its positively charged b-amino group and the 5 0 phosphate of G1197. Stereoconfiguration of the C7 carbon atom carrying this amino group is pivotal for orienting the antibiotic and its binding to tRNA. Indeed, inverting its stereo configuration dramatically diminished drug-induced miscoding (Uehara et al., 1976a) . In contrast, the C9-linked hydroxyl is not involved in any major interactions, as removal of this group or its methylation had no effect on miscoding (Uehara et al., 1976a) . Finally, any bulky substitutions at the terminal amino group of NEG will prevent the drug from fitting into its binding pocket. Consistently, its acylation prevented drug binding and miscoding (Uehara et al., 1976a) .
Binding in Site 1 Cannot Explain NEG Effect upon Translation Termination
One of the activities reported previously for NEG was inhibition of translation termination (Uehara et al., 1974) . We were unable to find any convincing rationale for this activity on the basis of NEG binding to Site 1. Aligning the 70S-NEG structure with those of the ribosome complexed with Class I release factors did not show any interference or specific interactions between the drug and either of the release factors ( Figures S5A and S5B) . However, binding of NEG to Site 5 in the large ribosomal subunit results in a steric clash with the amino acid residue Gln253 of T. thermophilus RF1 (Figures S5C and  S5D ). Competition between NEG and RF1 for mutually exclusive binding to the 70S ribosome is also indirectly supported by the observation that ribosome crystals containing RF1 significantly lose their diffraction ability upon soaking with NEG (data not shown). This could be the result of NEG-induced disorder in 70S-RF1 crystals. Nevertheless, it should be noted that even if binding of NEG in Site 5 interferes with peptide release, this activity has a negligible contribution to the overall antibiotic effect because none of the resistance mutations were found in the vicinity of this site. Figure 2A . Nucleotides 964-966 from h31 of the 16S rRNA, which are involved in NEG binding, are not shown for clarity. NEG structure is from the current work; TET is from PDB entry 4G5K (Jenner et al., 2013) . All structures were aligned based on h34 of the 16S rRNA. NEG and TET: Same Site, Different Modes of Action Besides NEG, antibiotics of two other classes, TET and SPC, interact with h34 in 16S rRNA (Borovinskaya et al., 2007b; Brodersen et al., 2001; Jenner et al., 2013; Pioletti et al., 2001) . While the binding site of SPC is separated from that of NEG by more than 20 Å , TET and NEG bind to overlapping sites, in which they share some of the interactions with 16S rRNA (Figure 5 ). Both antibiotics form extensive hydrogen-bonding interactions with the sugar-phosphate backbone of the h34 nucleotides 1197 and 1198. At the same time, they do not interact with the nucleobases, except for partial stacking of TET against C1054. The main difference in the binding modes of the two antibiotics with rRNA is that TET anchors onto the ribosome primarily through interactions with h34, forming only a single Mg 2+ -mediated interaction with the backbone of h31 nucleotide 966, whereas NEG exhibits multiple direct interactions with the backbone of nucleotides 965 and 966 from the h31 loop ( Figure 2F ). In spite of their overlapping binding sites in the ribosome, the mechanisms of TET and NEG action are quite different. NEG fits snugly between helices 34 and 31 of the 16S rRNA and the backbone of the tRNA anticodon in the A site ( Figure 5C ), while ribosome-bound TET clashes with the tRNA anticodon ( Figure 5D ). As a result of this difference, NEG likely increases the affinity of the tRNA to the ribosomal A site, while TET and its derivatives compete with aminoacyl-tRNA binding (Blanchard et al., 2004; Brodersen et al., 2000; Jenner et al., 2013) .
Idiosyncrasies in the contacts of NEG and TET with the ribosome prompted us to test the cross-resistance conferred by the previously known TET-resistance mechanisms and the newly discovered NEG r mutations. The NEG r mutations U1060A and A1197U rendered E. coli cells resistant to TET,
Molecular Cell
Miscoding Antibiotic Directly Enhances tRNA Binding whereas combining these mutations in the same ribosome restored the wild-type sensitivity for both TET and NEG ( Table  2 ), suggesting that the undisrupted secondary structure of h34 is required for efficient binding of both antibiotics. The TET r mutation G1058C (Ross et al., 1998 ) also increased NEG resistance (Table 2 ). In contrast, TET r mutation G966U (Dailidiene et al., 2002; Gerrits et al., 2002 Gerrits et al., , 2003 Nonaka et al., 2005) rendered cells hypersensitive to NEG (Table 2) , whereas NEG r mutation U1052G increased sensitivity to TET, accentuating the difference in interactions of these chemically dissimilar antibiotics with the ribosome. A unique mechanism of TET resistance involves the action of the ribosome protection proteins (e.g., TetM), which have been suggested to promote dissociation of the drug by transient binding to the ribosome and altering the conformation of the antibiotic binding site (Dö nhö fer et al., 2012; Spahn et al., 2001 ). Expression of TetM in E. coli BL21 cells increased TET MIC by 32-fold (Mikolajka et al., 2011) (Table 2) but had no effect on NEG sensitivity (Table 2 ). This result suggests that the TetM-induced alteration of the TET binding pocket does not trigger release of the bound NEG, further stressing the conclusion that NEG and TET establish substantially distinct interactions with the 30S ribosomal subunit.
The use of a ribosomal functional complex for the structural analysis made it possible to observe important interactions between NEG and tRNA, which likely stimulate tRNA binding and, as we propose, are critical for the mechanism of drug action. Our structure and the newly gained insights into the mode of NEG action can suggest future directions for optimizing the clinically relevant activities of the drug. For example, extending the carboxyl end of NEG or adding bulky substitutions to the N3 position ( Figure 1A) will likely lead to a clash with the A-site tRNA and acquiring ''TET-like'' activity at the expense of NEG-specific properties. In contrast, small substitutions at the amino terminus or at C8 may stabilize NEG binding to the ribosome and/or tRNA, potentially further improving its miscoding capacity. We believe that understanding the interactions and operation of NEG in its functional site in the ribosome will provide the structural framework for future improvement of this protein synthesis inhibitor for medical purposes.
Our results also show that the affinity of the aminoacyl-tRNA to the ribosome must be carefully balanced in order to provide efficient acceptor substrate binding without compromising accuracy and speed of translocation. Perturbing this balance by decreasing aminoacyl-tRNA affinity (e.g., by TET) or increasing it (e.g., by NEG) is detrimental for efficient protein synthesis.
EXPERIMENTAL PROCEDURES
Crystallographic Structure Determination T. thermophilus 70S ribosomes, unmodified tRNA i Met and tRNA Phe from E. coli were purified as previously described (Jü nemann et al., 1996; Polikanov et al., 2012; Schmitt et al., 1999) . Synthetic mRNA with the sequence 5 0 -GGC AAG GAG GUA AAA AUG UUC UAA-3 0 was obtained from IDT (Coralville). NEG was obtained from the Institute of Microbial Chemistry (Tokyo).
Ribosome-mRNA-tRNA complex was formed by programming of 5 mM 70S Tth ribosomes with 10 mM mRNA and incubation at 55 C for 10 min, followed by addition of 20 mM P-and A-site tRNA substrates (with minor changes from . Each of the last two steps was allowed to reach equilibrium for 10 min at 37 C. The final ionic conditions were as follows: 5 mM HEPES-KOH (pH 7.6), 50 mM KCl, 10 mM NH 4 Cl, and 10 mM Mg(CH 3 COO) 2 . Crystals were grown by the vapor diffusion method in sitting drops at 19 C and stabilized as described (Polikanov et al., 2012) with NEG included only in the last stabilization buffer (250 mM NEG final concentration). Diffraction data were collected at beamline 24ID-C at the Advanced Photon Source and beamline X25 at the Brookhaven National Laboratory. All crystals belonged to the primitive orthorhombic space group P2 1 2 1 2 1 with approximate unit cell dimensions of 210 Å 3 450 Å 3 620 Å and contained two copies of the 70S ribosome per asymmetric unit. The initial molecular replacement solutions were refined by rigid body refinement with the ribosome split into multiple domains, followed by positional and individual B factor refinement. The statistics for data processing and refinement are shown in Table 1 .
Selection and Analysis of NEG-and TET-Resistant Mutants
To isolate NEG resistant mutants, E. coli SQ110DTC cells (Orelle et al., 2013) were grown overnight at 37 C in LB medium containing selective antibiotic markers (50 mg/ml SPC and 50 mg/ml KAN). The culture was diluted to OD 600 = 0.05 and, upon reaching mid exponential phase (OD 600 = 0.5), ca. 10 9 cells ($1 OD 600 of the culture) were plated on a LB-agar plate containing 160 mg/ml NEG (5-fold MIC). Several colonies appeared on the plate after overnight incubation at 37 C. 16S and 23S genes were PCR amplified from the resistant colonies and were sequenced (Orelle et al., 2013) .
The T1060A and A1197T mutations were introduced in the 16S rRNA gene of plasmid pAM552 using the QuikChange Lightning Multi Site mutagenesis kit (Agilent Technologies). After verifying the presence of the mutation, the mutant plasmids were introduced into E. coli SQ171 DtolC strain (Asai et al., 1999; Bollenbach et al., 2009 ). MICs were determined by microbroth dilution method.
Plasmid pAM552 was engineered as follows: a 5.6-kb DNA fragment containing E. coli rrnB operon starting from the PL promoter and including both T1 and T2 terminators was PCR amplified from the pLK35 plasmid (Douthwaite et al., 1989) using primers Not-PL-rrnB (CCCGCGGCCGCGATCTCTCACC TACCAAACAATGCC) and Asc-Pl-rrnB2 (CCCGGCGCGCCGGCTTGTAGAT ATGACGACAGGAAGA). The bla-ori segment of the pGEX-2T plasmid was PCR amplified using primers Not-pGEXR (CGGGCGGCCGCCAGCAAAAG GCCAGGAACCGTAAAAAG) and Asc-pGEXD (CCCGGCGCGCCGGGAAA TGTGCGCGGAACCCC). DNA fragments were cut with NotI and AscI restriction enzymes and ligated together. A unique PstI site was then introduced at the end of the bla gene by site-directed mutagenesis. This plasmid was further modified by introducing pTrc promoter in front of the bla gene, NdeI restriction enzyme at the bla gene start codon, and Trp terminator followed by the PstI site after the end of the bla gene.
Toe-Printing Assay
Toe-printing analysis (Hartz et al., 1988) was performed following in vitro coupled transcription-translation reactions in the PURE system (New England Biolabs) with no antibiotic or in the presence of 100 mM thiostrepton (THS), NEG, VIO, KAN, or TET. Template for osmC was amplified from genomic DNA, and overlapping PCR was used to generate RST2 (Orelle et al., 2013) .
Translocation Assay
Translocation assay was carried out using the phage T4 gene 32 template (m291) essentially as described by Shoji et al. (2006) with minor modifications as described in Polikanov et al. (2014a) .
In Vivo Miscoding Activity
The TGA stop codon was inserted between codons 109 and 110 of the bla gene of pBR322 using the QuikChange kit (Agilent Technologies) and the primer (CA CCA GTC ACA GAA AAG TAG CAT CTT ACG GAT GGC AT). The resulting plasmid pBR322bla-stop was transformed into E. coli TB-1 cells.
Cells containing pBR322bla-stop were grown at 37 C overnight in LB medium with selective antibiotics (TET 10 mg/ml and STR 25 mg/ml). Culture was diluted to OD 600 = 0.05 and allowed to reach late exponential phase (OD 600 $1). A total of 1.5 ml of cell culture were mixed with 13.5 ml of soft agar and poured into rectangular LB agar plates that contained 25 mg/ml ampicillin or no antibiotic. Filter discs containing PAR (7.5 mg), NEG (30 mg), or SPE (10 mg) were placed on top of the solidified soft agar. Following overnight incubation at 37 C, plates were sprayed with a solution of nitrocefin (10 mg/ml in DMSO), incubated at room temperature for 2 hr, and photographed. The color of the entire image was adjusted to better visualize staining.
Determining the Effect of TetM Expression on Resistance to NEG Plasmid pET46LIC-TetM (kindly provided by Drs. Wilson and Starosta, Gene Center, University of Munich) or the empty vector pET11a were transformed into E. coli BL21(DE3) cells. Following 1 hr incubation at 37 C of the transformed culture in LB medium, ampicillin was added to a final concentration of 100 mg/ml, and incubation continued overnight. Cultures were then diluted to OD 600 = 0.05, and upon reaching OD 600 = 0.2, TetM expression was induced with 0.5 mM isopropyl-b-D-1-thiogalactopyranoside, and MICs for TET and NEG were determined.
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Coordinates and structure factors for the Tth 70S ribosome in complex with NEG were deposited in the RCSB Protein Data Bank with accession codes 4RBH, 4RBI, 4RBJ, and 4RBK. 
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